Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.sabcs18-ct032 ◽

2019 ◽

Author(s):

Helena Yu ◽

Myung-Ju Ahn ◽

Sang-We Kim ◽

Byoung Chul Cho ◽

Lecia Sequist ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.am2019-ct033 ◽

2019 ◽

Cited By ~ 3

Author(s):

Lecia V. Sequist ◽

Jong Seok Lee ◽

Ji-Youn Han ◽

Wu-Chou Su ◽

James Chih-Hsin Yang ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.sabcs18-ct033 ◽

2019 ◽

Author(s):

Lecia V. Sequist ◽

Jong Seok Lee ◽

Ji-Youn Han ◽

Wu-Chou Su ◽

James Chih-Hsin Yang ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Phase Ib ◽

Epidermal Growth ◽

The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma

Surgery Today ◽

10.1007/s00595-011-4514-2 ◽

2011 ◽

Vol 41 (6) ◽

pp. 818-823 ◽

Cited By ~ 3

Author(s):

Daigo Kawano ◽

Tokujiro Yano ◽

Fumihiro Shoji ◽

Kensaku Ito ◽

Yosuke Morodomi ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Signal Activation ◽

Inhibitor Treatment

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3074 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3074-3074 ◽

Cited By ~ 7

Author(s):

S. Di Cosimo ◽

P. Matar ◽

F. Rojo ◽

M. Guzman ◽

S. Rodriguez ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

In silico study of 1-benzoyl-3-methylthiourea derivatives activity as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidates

Chemical Data Collections ◽

10.1016/j.cdc.2021.100741 ◽

2021 ◽

pp. 100741

Author(s):

Ruswanto Ruswanto ◽

Amir M. Miftah ◽

Daryono H. Tjahjono ◽

Siswandono

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

In Silico ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

In Silico Study ◽

The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers

Journal of Biological Chemistry ◽

10.1074/jbc.m605136200 ◽

2006 ◽

Vol 282 (5) ◽

pp. 2840-2850 ◽

Cited By ~ 74

Author(s):

Hui K. Gan ◽

Francesca Walker ◽

Antony W. Burgess ◽

Angela Rigopoulos ◽

Andrew M. Scott ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Egfr Tyrosine Kinase ◽

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3074 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3074-3074

Author(s):

S. Di Cosimo ◽

P. Matar ◽

F. Rojo ◽

M. Guzman ◽

S. Rodriguez ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-1004-0019 ◽

2005 ◽

Vol 11 (19) ◽

pp. 7080s-7086s ◽

Cited By ~ 38

Author(s):

Fook T. Lee ◽

Angela J. Mountain ◽

Marcus P. Kelly ◽

Cathrine Hall ◽

Angela Rigopoulos ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Egfr Signaling ◽

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

International Journal of Cancer ◽

10.1002/ijc.1557 ◽

2001 ◽

Vol 94 (6) ◽

pp. 774-782 ◽

Cited By ~ 133

Author(s):

Neil G. Anderson ◽

Tawhid Ahmad ◽

Kai Chan ◽

Richard Dobson ◽

Nigel J. Bundred

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Erbb2 Overexpression